Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Diclofenac Sodium Topical Solution, 1.5%w/w.
It is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.
The group now has more than 185 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
